Law Offices of Howard G. Smith announces an investigation on behalf of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GOSSAMER BIO, INC. (GOSS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On February 23, 2026, Gossamer disclosed that results for its Phase 3 PROSERA study of seralutinib for the treatment of pulmonary arterial hypertension had failed to meet the primary endpoint, citing patients at Latin American sites performing particularly well on placebo due to enrollment of a heavily-treated lower-risk population.
On this news, Gossamer’s stock price fell $1.71, or 80.3%, to close at $0.42 per share on February 23, 2026, thereby injuring investors.
Contact Us to Participate or Learn More:
If you purchased Gossamer securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, Pennsylvania 19020
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260403614987/en/
